(Deamino-Cys1,b-(3-pyridyl)-D-Ala2,Arg8)-Vasopressin trifluoroacetate salt

CAS : 136105-89-0

Ref. 3D-FD108862

Informations sur le produit

• Nom: (Deamino-Cys1,b-(3-pyridyl)-D-Ala2,Arg8)-Vasopressin trifluoroacetate salt
• Synonymes: d(D-3Pal)VP, [Deamino-Cys1, D-3-(Pyridyl)Ala2, Arg8] Vasopressin3-Mercaptopropionyl-?-(3-pyridyl)-D-Ala-Phe-Gln-Asn-Cys-Pro-Arg-Gly -NH2 trifluoroacetate salt (Disulfide bond), Argipressin, 1-deamino-3-(3'-pyridyl)-ala(2)-, 1-Deamino-3-(3'-pyridyl)-2-ala-argipressin, Argipressin, 1-deamino-3-(3'-pyridyl)alanine(2)-, d(D-3-Pal)VP, 1-{[7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-6,9,12,15,18-pentaoxo-16-(pyridin-3-ylmethyl)-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-4-yl]carbonyl}prolyl-N~5~-(diaminomethylidene)ornithylglycinamide, 3-Mercaptopropionyl-Beta-3-Pyridyl-D-Ala-Phe-Gln-Asn-Cys-Pro-Arg-Gly-Nh2

Description

DDAVP is an analogue of vasopressin, which belongs to the class of inositol phosphates. It is a potent agonist for the V1 receptor and has a higher affinity for this receptor than vasopressin. DDAVP also has antagonist properties at the V2 receptor. The biological activity of DDAVP is mediated by its ability to increase phospholipase A2 activity and cause the release of arachidonic acid from membrane phospholipids. This activation causes an increase in prostaglandin synthesis, leading to increased vascular permeability and hypotension. DDAVP may also have antidiuretic effects due to its antagonism of oxytocin receptors.

• Marque: Biosynth

Propriétés chimiques

• Masse moléculaire: 1,054.21 g/mol
• Formule: C₄₅H₆₃N₁₅O₁₁S₂
• Degré de pureté: Min. 95%